AI-assisted analytics empower research infrastructures
"Our vision is to equip research infrastructures with AI-assisted analytics to better understand the dynamics of their user communities and complex collaborative ecosystems," explains Dr. Katharina C. Cramer , historian and social scientist at the Center for Advanced Security, Strategic and Integration Studies (CASSIS) of the University of Bonn. Together with Kristofer R. Söderström (Lund University) and Nicolas V. Rüffin (CASSIS), she is developing AI-assisted analytics that deciphers the intellectual, social, and geographical dynamics within user communities and collaborative ecosystems. Their solution will support research infrastructures in their ability to make informed decisions, fostering their socio-economic impact and innovative potentials. During the prototyping project "Tiller - an AI-assisted platform for research infrastructures and their user communities," Dr. Katharina C. Cramer and her team partner with the European XFEL, an international research infrastructure that provides the strongest X-ray laser beam in the world to thousands of users.
Making weeding robots smart and bio-diversity aware
Coldex - Nasal spray provides protection from viral infections
A team at the University Hospital in Bonn is developing "Coldex", a nasal spray for the prophylaxis of infections with respiratory viruses. The spray activates an alarm system that warns cells of a viral threat, and triggers an antiviral defense system that allows cells to efficiently fight and repel invading viruses. "We use a synthetic immunostimulatory nucleic acid to turn on our body’s own antiviral defense system" says Dr. Christine Wuebben, explaining the mechanism of the prototype. The approach was developed by a team of scientists in the group of Gunther Hartmann at the Institute of Clinical Chemistry and Clinical Pharmacology and the Cluster of Excellence ImmunoSensation2 . The spray has potential to slow seasonal cold outbreaks and perhaps even prevent future pandemics of respiratory viruses. The team is now working on the pre-clinical development of the prototype and hope to rapidly bring it onto the market.